News & Events

Press releases

Pneumagen Announces Appointment of John Beadle as Non-Executive Director

READ MORE...

Pneumagen to present on further significant development for its lead product, Neumifil at BioTrinity 2022

READ MORE...

Pneumagen Raises £3.8 million to Advance the Phase II Clinical Development of Neumifil, a Pan-antiviral, Intranasal Drug for the Prophylaxis and Treatment of Viral Respiratory Tract Infections (RTIs)

READ MORE...

Pneumagen initiates Phase 1 trial of Neumifil, a novel, intranasal pan anti-viral therapeutic for the prophylaxis and treatment of viral Respiratory Tract Infections

READ MORE...

Pneumagen Appoints New Head of Research to Expand its Anti-Viral Pipeline leveraging its Proprietary GlycoTarge™ Platform

READ MORE...

Pneumagen Announces Neumifil™ is Efficacious In an Established Model of COVID-19 Infection

READ MORE...

Pneumagen Announces £2.5m fundraising to advance universal treatment for viral respiratory infections into the clinic this year

READ MORE...

Pneumagen’s Neumifil for combating COVID-19 featured in SCRIP’s 10 to watch at BIO-Europe Digital

READ MORE...

Pneumagen Announces Scientific Advisory Board and Development Team Appointments

READ MORE...

Event information

Bio€quity Europe in San Sebastian, Spain | May 12th – 14th 2024

READ MORE...

BioTrinity in London | April 23 – 24th 2024

READ MORE...

J.P. Morgan Healthcare Conference and Biotech Showcase I January 8th – 11th 2024

READ MORE...

Jefferies London Healthcare Conference I November 14th – 16th 2023

READ MORE...

BARDA Industry Day in Washington I November 13th-14th 2023

READ MORE...

BIO-Europe in Munich I November 6th-8th 2023

READ MORE...

Bio€quity Europe in Dublin | May 14th – 16th 2023

READ MORE...

BioTrinity in London | April 25 – 26th 2023

READ MORE...

Biotech Showcase / JPM Week | January 9th – 11th 2023

READ MORE...